Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.26
CNMD's Cash to Debt is ranked higher than
52% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. CNMD: 0.26 )
CNMD' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.26

Equity to Asset 0.53
CNMD's Equity to Asset is ranked higher than
61% of the 447 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. CNMD: 0.53 )
CNMD' s 10-Year Equity to Asset Range
Min: 0.29   Max: 0.93
Current: 0.53

0.29
0.93
Interest Coverage 10.07
CNMD's Interest Coverage is ranked higher than
51% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. CNMD: 10.07 )
CNMD' s 10-Year Interest Coverage Range
Min: 1.24   Max: 128
Current: 10.07

1.24
128
F-Score: 5
Z-Score: 3.05
M-Score: -2.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 6.93
CNMD's Operating margin (%) is ranked higher than
77% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. CNMD: 6.93 )
CNMD' s 10-Year Operating margin (%) Range
Min: -0.71   Max: 20.38
Current: 6.93

-0.71
20.38
Net-margin (%) 4.15
CNMD's Net-margin (%) is ranked higher than
74% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. CNMD: 4.15 )
CNMD' s 10-Year Net-margin (%) Range
Min: -5.13   Max: 12.98
Current: 4.15

-5.13
12.98
ROE (%) 5.20
CNMD's ROE (%) is ranked higher than
74% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. CNMD: 5.20 )
CNMD' s 10-Year ROE (%) Range
Min: -4.42   Max: 18.46
Current: 5.2

-4.42
18.46
ROA (%) 2.84
CNMD's ROA (%) is ranked higher than
74% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. CNMD: 2.84 )
CNMD' s 10-Year ROA (%) Range
Min: -1.94   Max: 12.01
Current: 2.84

-1.94
12.01
ROC (Joel Greenblatt) (%) 14.87
CNMD's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. CNMD: 14.87 )
CNMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1.56   Max: 61.14
Current: 14.87

-1.56
61.14
Revenue Growth (%) 3.20
CNMD's Revenue Growth (%) is ranked higher than
72% of the 341 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. CNMD: 3.20 )
CNMD' s 10-Year Revenue Growth (%) Range
Min: -0.1   Max: 40.8
Current: 3.2

-0.1
40.8
EBITDA Growth (%) 5.80
CNMD's EBITDA Growth (%) is ranked higher than
80% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. CNMD: 5.80 )
CNMD' s 10-Year EBITDA Growth (%) Range
Min: -35.8   Max: 43.5
Current: 5.8

-35.8
43.5
EPS Growth (%) 6.80
CNMD's EPS Growth (%) is ranked higher than
79% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. CNMD: 6.80 )
CNMD' s 10-Year EPS Growth (%) Range
Min: -72   Max: 49.7
Current: 6.8

-72
49.7
» CNMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CNMD Guru Trades in Q4 2013

Chuck Royce 82,200 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Mario Gabelli 93,200 sh (-0.75%)
Ken Fisher 74,200 sh (-18.82%)
John Keeley 54,620 sh (-23.9%)
Paul Tudor Jones 7,300 sh (-34.23%)
» More
Q1 2014

CNMD Guru Trades in Q1 2014

Jim Simons 45,681 sh (New)
Joel Greenblatt 13,467 sh (New)
Steven Cohen 14,110 sh (New)
Paul Tudor Jones 24,923 sh (+241.41%)
John Keeley 54,620 sh (unchged)
Chuck Royce 82,200 sh (unchged)
Mario Gabelli 93,000 sh (-0.21%)
Ken Fisher 67,300 sh (-9.3%)
» More
Q2 2014

CNMD Guru Trades in Q2 2014

Joel Greenblatt 168,447 sh (+1150.81%)
Jim Simons 210,760 sh (+361.37%)
Chuck Royce 82,200 sh (unchged)
Steven Cohen 27,100 sh (unchged)
Ken Fisher 67,300 sh (unchged)
Mario Gabelli 92,300 sh (-0.75%)
Paul Tudor Jones 22,370 sh (-10.24%)
John Keeley 34,641 sh (-36.58%)
» More
Q3 2014

CNMD Guru Trades in Q3 2014

Ken Fisher 413,810 sh (+514.87%)
Paul Tudor Jones 24,642 sh (+10.16%)
John Keeley 34,641 sh (unchged)
Chuck Royce 82,200 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Mario Gabelli 92,100 sh (-0.22%)
Jim Simons 180,481 sh (-14.37%)
» More
» Details

Insider Trades

Latest Guru Trades with CNMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Sold Out 0.09%$36.53 - $45.36 $ 44.8613%0
Ken Fisher 2014-09-30 Add 514.87%0.03%$36.53 - $45.36 $ 44.8613%413810
Joel Greenblatt 2014-06-30 Add 1150.81%0.09%$42.23 - $49.65 $ 44.86-1%168447
John Keeley 2014-06-30 Reduce -36.58%0.01%$42.23 - $49.65 $ 44.86-1%34641
Joel Greenblatt 2014-03-31 New Buy0.01%$41.33 - $48.54 $ 44.861%13467
Joel Greenblatt 2013-12-31 Sold Out 0.02%$33.25 - $42.48 $ 44.8618%0
John Keeley 2013-12-31 Reduce -23.9%0.01%$33.25 - $42.48 $ 44.8618%54620
Joel Greenblatt 2013-09-30 Reduce -61.01%0.04%$31.07 - $33.76 $ 44.8638%19019
Joel Greenblatt 2013-06-30 Reduce -41.34%0.06%$30.42 - $34.04 $ 44.8638%48778
John Keeley 2013-06-30 Add 43.21%0.01%$30.42 - $34.04 $ 44.8638%63970
John Keeley 2013-03-31 Add 27.74%0.01%$27.95 - $34.29 $ 44.8648%44670
Ken Fisher 2013-03-31 Add 39.12%$27.95 - $34.29 $ 44.8648%91400
John Keeley 2012-12-31 New Buy0.02%$25.71 - $29.33 $ 44.8663%34970
Ken Fisher 2012-06-30 Add 65.49%$26.01 - $30.27 $ 44.8660%65700
Joel Greenblatt 2012-03-31 Add 39.72%0.04%$26.44 - $30.47 $ 44.8666%57083
Richard Pzena 2012-03-31 Sold Out 0.01%$26.44 - $30.47 $ 44.8666%0
Ken Fisher 2012-03-31 New Buy$26.44 - $30.47 $ 44.8666%39700
Richard Pzena 2011-12-31 Reduce -87.21%0.09%$21.72 - $27.83 $ 44.8675%49272
Joel Greenblatt 2011-12-31 Add 53.81%0.05%$21.72 - $27.83 $ 44.8675%40854
Joel Greenblatt 2011-09-30 Add 38.04%0.03%$20.81 - $29.38 $ 44.8683%26561
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 40.10
CNMD's P/E(ttm) is ranked higher than
80% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 85.90 vs. CNMD: 40.10 )
CNMD' s 10-Year P/E(ttm) Range
Min: 9.88   Max: 755.25
Current: 40.1

9.88
755.25
P/B 2.10
CNMD's P/B is ranked higher than
82% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.88 vs. CNMD: 2.10 )
CNMD' s 10-Year P/B Range
Min: 0.61   Max: 2.27
Current: 2.1

0.61
2.27
P/S 1.70
CNMD's P/S is ranked higher than
82% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.41 vs. CNMD: 1.70 )
CNMD' s 10-Year P/S Range
Min: 0.48   Max: 1.83
Current: 1.7

0.48
1.83
PFCF 24.90
CNMD's PFCF is ranked higher than
90% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CNMD: 24.90 )
CNMD' s 10-Year PFCF Range
Min: 7.44   Max: 2046
Current: 24.9

7.44
2046
EV-to-EBIT 27.26
CNMD's EV-to-EBIT is ranked higher than
81% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 64.69 vs. CNMD: 27.26 )
CNMD' s 10-Year EV-to-EBIT Range
Min: -226.3   Max: 153.1
Current: 27.26

-226.3
153.1
PEG 2.86
CNMD's PEG is ranked higher than
93% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CNMD: 2.86 )
CNMD' s 10-Year PEG Range
Min: 1.23   Max: 240.33
Current: 2.86

1.23
240.33
Shiller P/E 50.70
CNMD's Shiller P/E is ranked higher than
86% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CNMD: 50.70 )
CNMD' s 10-Year Shiller P/E Range
Min: 11.93   Max: 52.22
Current: 50.7

11.93
52.22
Current Ratio 3.17
CNMD's Current Ratio is ranked higher than
75% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. CNMD: 3.17 )
CNMD' s 10-Year Current Ratio Range
Min: 1.37   Max: 12.38
Current: 3.17

1.37
12.38
Quick Ratio 1.83
CNMD's Quick Ratio is ranked higher than
68% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. CNMD: 1.83 )
CNMD' s 10-Year Quick Ratio Range
Min: 0.48   Max: 8.38
Current: 1.83

0.48
8.38

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.80
CNMD's Dividend Yield is ranked higher than
68% of the 185 Companies
in the Global Medical Devices industry.

( Industry Median: 1.39 vs. CNMD: 1.80 )
CNMD' s 10-Year Dividend Yield Range
Min: 0.5   Max: 2.22
Current: 1.8

0.5
2.22
Dividend Payout 0.72
CNMD's Dividend Payout is ranked higher than
80% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CNMD: 0.72 )
CNMD' s 10-Year Dividend Payout Range
Min: 0.4   Max: 2.86
Current: 0.72

0.4
2.86
Yield on cost (5-Year) 1.80
CNMD's Yield on cost (5-Year) is ranked higher than
57% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 1.59 vs. CNMD: 1.80 )
CNMD' s 10-Year Yield on cost (5-Year) Range
Min: 0.5   Max: 2.22
Current: 1.8

0.5
2.22
Share Buyback Rate 0.90
CNMD's Share Buyback Rate is ranked higher than
92% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -1.10 vs. CNMD: 0.90 )
CNMD' s 10-Year Share Buyback Rate Range
Min: 1.6   Max: -16.1
Current: 0.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 71.20
CNMD's Price/Tangible Book is ranked higher than
55% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.71 vs. CNMD: 71.20 )
CNMD' s 10-Year Price/Tangible Book Range
Min: 2.46   Max: 174.94
Current: 71.2

2.46
174.94
Price/DCF (Projected) 1.40
CNMD's Price/DCF (Projected) is ranked higher than
93% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CNMD: 1.40 )
CNMD' s 10-Year Price/DCF (Projected) Range
Min: 0.5   Max: 1.74
Current: 1.4

0.5
1.74
Price/Median PS Value 1.50
CNMD's Price/Median PS Value is ranked higher than
64% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. CNMD: 1.50 )
CNMD' s 10-Year Price/Median PS Value Range
Min: 0.49   Max: 2.72
Current: 1.5

0.49
2.72
Price/Peter Lynch Fair Value 4.20
CNMD's Price/Peter Lynch Fair Value is ranked higher than
95% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CNMD: 4.20 )
CNMD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.38   Max: 104.57
Current: 4.2

0.38
104.57
Price/Graham Number 11.20
CNMD's Price/Graham Number is ranked higher than
74% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CNMD: 11.20 )
CNMD' s 10-Year Price/Graham Number Range
Min: 1.26   Max: 32.17
Current: 11.2

1.26
32.17
Earnings Yield (Greenblatt) 3.70
CNMD's Earnings Yield (Greenblatt) is ranked higher than
81% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. CNMD: 3.70 )
CNMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 13.1
Current: 3.7

0.7
13.1
Forward Rate of Return (Yacktman) 13.87
CNMD's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. CNMD: 13.87 )
CNMD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.9   Max: 21.2
Current: 13.87

-13.9
21.2

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:EC8.Germany,
Conmed Corp was incorporated under the laws of the State of New York in 1970. It is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and monitoring. The Company's products serve the clinical areas, surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. Effective January 1, 2013, the Company is accounting and reporting business as a single segment entity engaged in the development, manufacturing and sale on a basis of surgical devices and related equipment. The business is derived from sales in orthopedic surgery product lines, including sports medicine, powered surgical instruments and sports biologics and tissue. These lines are marketed under a number of reputable brands, including Hall, CONMED Linvatec, Concept and Shutt. The surgical visualization product line offers endoscopic imaging and capture devices for the complete spectrum of surgical needs including 2DHD and 3DHD vision technologies. The general surgery product line offers in the areas of advanced energy, endomechanical instrumentation, gastrointestinal, pulmonary and patient monitoring. The products are distributed domestically directly to more than 6,000 hospitals and other healthcare institutions as well as through medical specialty distributors and surgeons. The operation of Company are subject, to a number of environmental laws and regulations governing, among other things, air emissions, wastewater discharges, the use, handling and disposal of hazardous substances and wastes, soil and groundwater remediation and employee health and safety.
» More Articles for CNMD

Headlines

Articles On GuruFocus.com
CONMED Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference Dec 11 2014 
CONMED Corporation to Announce Third Quarter 2014 Financial Results on October 23, 2014 Oct 15 2014 
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 
Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 
Weekly CEO Sells Highlight: Profire energy Inc, Graphic Packaging Holding Co, Seagate Technology PLC Aug 04 2014 
My 5 Favorite High Beta Health Care Dividend Stocks Aug 02 2013 
CONMED Corp. (CNMD) Vice President/Finance/CFO Robert D Jr Shallish sells 6,151 Shares Feb 07 2011 
CONMED Corp. Reports Operating Results (10-Q) Nov 02 2010 
CONMED Corp. Reports Operating Results (10-Q) Aug 03 2010 
CONMED Corp. Reports Operating Results (10-Q) May 05 2010 

More From Other Websites
CONMED CORP Files SEC form 8-K, Change in Directors or Principal Officers Dec 12 2014
CONMED Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference Dec 11 2014
CONMED Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference Dec 11 2014
CONMED CORP Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,... Dec 09 2014
CONMED Corporation Announces Management Transitions Dec 09 2014
CONMED Corporation Announces Management Transitions Dec 09 2014
CONMED Corporation Issues a Voluntary Device Correction for PadPro and R2 Multi-function... Nov 25 2014
CONMED Corporation to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 20 2014
CONMED CORP Files SEC form 8-K, Other Events Nov 19 2014
CONMED Corporation Announces Quarterly Cash Dividend Nov 18 2014
CONMED Corporation Announces Quarterly Cash Dividend Nov 18 2014
Curt Hartman Named President and CEO of CONMED Corporation Nov 10 2014
CONMED CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Nov 10 2014
Curt Hartman Named President and CEO of CONMED Corporation Nov 10 2014
CONMED CORP Financials Oct 31 2014
CONMED CORP Files SEC form 10-Q, Quarterly Report Oct 24 2014
CONMED Q3 Earnings Rise but Revenues Fall Oct 24 2014
Conmed posts 3Q profit Oct 23 2014
Conmed posts 3Q profit Oct 23 2014
CONMED CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 23 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK